Trial Profile
A phase II/III study of Eculizumab in patients for the treatment of Antibody-mediated rejection following renal transplantation
Status:
Planning
Phase of Trial:
Phase II/III
Latest Information Update: 23 Mar 2022
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 28 Apr 2015 New trial record